Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.1%

329 terminated/withdrawn out of 2331 trials

Success Rate

83.6%

-3.0% vs industry average

Late-Stage Pipeline

45%

1050 trials in Phase 3/4

Results Transparency

32%

538 of 1675 completed trials have results

Key Signals

131 recruiting538 with results282 terminated47 withdrawn

Enrollment Performance

Analytics

Phase 3
686(32.5%)
Phase 2
589(27.9%)
Phase 1
392(18.5%)
Phase 4
364(17.2%)
N/A
83(3.9%)
2114Total
Phase 3(686)
Phase 2(589)
Phase 1(392)
Phase 4(364)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2331)

Showing 20 of 2331 trials
NCT06444451Phase 2Terminated

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Role: lead

NCT07629960Phase 1Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Role: collaborator

NCT06290128Phase 3Active Not Recruiting

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Role: lead

NCT01747759Not ApplicableCompleted

Evaluation of a Preoperative Education in Total Knee Arthroplasty

Role: collaborator

NCT06015308Phase 2Completed

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Role: lead

NCT07688213Phase 2Recruiting

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

Role: lead

NCT07088068Phase 3Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Role: lead

NCT07634692Completed

An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia

Role: lead

NCT05668013Phase 2Active Not Recruiting

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Role: collaborator

NCT05107115Phase 2Completed

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

Role: lead

NCT05039840Phase 2Active Not Recruiting

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Role: lead

NCT07290803Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Role: lead

NCT03992417Active Not Recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Role: lead

NCT07325292Phase 3Recruiting

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Role: lead

NCT06081894Phase 3Active Not Recruiting

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Role: collaborator

NCT07112378Phase 3Recruiting

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Role: collaborator

NCT01065142Not ApplicableActive Not Recruiting

ETIC (Therapeutic Education in Heart Failure)

Role: collaborator

NCT06087627Active Not Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

Role: lead

NCT07615192Recruiting

RSV Immunisation Status in Queensland (Australia)

Role: lead

NCT01973881Recruiting

Quantitative MRI for Myelofibrosis

Role: collaborator